-
Amway Co., Ltd.: Comprehensive layout of the "2+4" field, focusing on the main business of polyurethane synthetic leather and composite materials
Time of Update: 2022-09-30
Customers are in the stage of cultivating and laying foundations, and the cooperation has been advanced in an orderly manner and has achieved initial results Amway shares said at the 2021 annual performance briefing held recently that the company's products have differences and characteristics, good quality, stable quality, good innovation ability, and advantages.
-
Amway Co., Ltd.: Comprehensive layout of the "2+4" field, focusing on the main business of polyurethane synthetic leather and composite materials
Time of Update: 2022-09-30
Customers are in the stage of cultivating and laying foundations, and the cooperation has been advanced in an orderly manner and has achieved initial results Amway shares said at the 2021 annual performance briefing held recently that the company's products have differences and characteristics, good quality, stable quality, good innovation ability, and advantages.
-
4 pathogenic bacterial co-infections! Patients with nephrotic syndrome are complicated by severe pneumonia
Time of Update: 2022-09-30
2022-5-14In the morning, the endocrinology department sent the morning sputum specimen of the patient to the microbial room for bacterial culture and smear to check the bacteria for two examinations, the smear Gram stain can see more gram-positive mycelia filamentosis, weak acid-resistant staining is positive (Figure 2), the laboratory telephone contact clinical, smear preliminary consideration of Nocardia infection, specific identification results and other follow-up culture.
-
Deyuan Pharmaceutical Co., Ltd. has approved batch production of Class 4 Acarbose Tablets and deemed it to have been reviewed
Time of Update: 2022-03-07
On February 10, Deyuan Pharmaceutical, a company listed on the Beijing Stock Exchange, issued an announcement stating that the company's acarbose tablets, which were reported as imitations of Category 4, were batch-produced and deemed to have been reviewed .
-
4 polymerizers of Cangzhou Refining & Chemical Co., Ltd. were successfully hoisted in place
Time of Update: 2021-06-04
In order to ensure the safety and controllability of the project implementation process, Refining Department IV, Equipment Engineering Department, Sinopec Fifth Construction Company, Supervision Company, and special Bohai company hoisting experts held two special meetings, repeated calculations and studies, optimized the hoisting plan, and finally decided to use a 130-ton crane The best plan is to coordinate the lifting of the main crane and the tail of the 70-ton crane.
-
Hengrui Pharmaceutical Co., Ltd. 4 directors, supervisors and senior executives reduce shares through centralized bidding
Time of Update: 2019-12-09
Pharmaceutical intelligence news learned that on December 6, Hengrui pharmaceutical released a notice on the plan of reducing shares held by directors, supervisors and senior executives through centra
-
Pharmaceutical Co., Ltd. has been appraised; Huahai 4 + 7 varieties have entered the Bureau strongly; Hengrui has made its first imitation
Time of Update: 2019-11-14
As of November 14, the acceptance number of CDE acceptance consistency evaluation reached 1569 (435 varieties of 447 enterprises) According to the supplementary application, the same below); 288 (116
-
Shijiazhuang No.4 Pharmaceutical Co., Ltd. leads MAH enterprise, and Qilu and Huahai are "spokesmen" of consistency evaluation enterprises
Time of Update: 2019-08-14
In order to fully mobilize the enthusiasm of R & D personnel and promote drug innovation, optimize resource allocation and inhibit low-level repeated construction, implement the main responsibility of
-
4 pharmaceutical companies and 5 product specifications cut prices in Sichuan, Hengrui, Shuanglu, Huiling, Xiehe Pharmaceutical Co., Ltd
Time of Update: 2019-03-08
On March 7, Sichuan Pharmaceutical Machinery centralized purchase center issued the notice of Sichuan Chuanyao Zhao [2019] No 16 on the price reduction of 5 drugs such as epirubicin hydrochloride Acco
-
CTLA-4 monoclonal antibody cs1002 independently developed by cornerstone Pharmaceutical Co., Ltd. has been approved for clinical use
Time of Update: 2018-08-28
August 28, 2018 / Meitong news agency / -- Cornerstone Pharmaceutical (Suzhou) Co., Ltd (hereinafter referred to as "cornerstone pharmaceutical") today announced that the clinical trial of its indepen
-
of class 4 in Wuhan Biological Engineering Co., Ltd. was accepted
Time of Update: 2014-12-01
The company said that the product is an effective supplement to the existing product dust mite skin prick diagnostic kit, which is conducive to further enriching the product line According to the intr